Fistula News and Research

RSS

A Fistula is an abnormal opening or passage between two organs or between an organ and the surface of the body. Fistulas may be caused by injury, infection, or inflammation, or may be created during surgery.

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

OTSC placement therapy is safe, effective for closure of gastrointestinal defects

An international multicenter study reports that over-the-scope clip (OTSC) placement is a safe and effective therapy for the closure of gastrointestinal (GI) defects, which includes anastomotic leaks, fistulae and perforations.

26 Oct 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

Patient goes on fishing trip after undergoing complex brain surgery

Just two weeks after undergoing delicate and complex brain surgery for a life-threatening condition, Bill Abt's surgeon cleared him to take a previously scheduled fishing trip.

9 Jul 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

CT-guided IRE therapy offers safe, feasible primary local treatment for advanced pancreatic cancer

A small group of patients with locally advanced unresectable pancreatic carcinoma suffered no major ill effects-pancreatitis or fistula formation-after undergoing percutaneous CT-guided irreversible electroporation (IRE)-a nonthermal ablation technology that is safe near vascular and ductal structures-as a therapy.

8 May 2014

Edna Adan named inaugural recipient of Renfield Foundation Award for Global Women's Health

Following an intense selection process, Edna Adan has been named the inaugural recipient of the University of Pennsylvania School of Nursing Renfield Foundation Award for Global Women's Health. The award will be presented to Adan on May 15, 2014 and includes a $100,000 cash prize which will be presented biennially to a leader in the field of global women's health.

21 Apr 2014

Loyola surgeon successfully performs operation on patient suffering from rare disorder

Jarely Sanchez is an affectionate, energetic little girl who loves ballet. "Everyone she meets, she connects with," said her father, Jose Angel Ulloa. "She's like a magnet." But for more than a week, the three-year-old girl wasn't herself.

4 Mar 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Conventional echocardiography increases accuracy of pre-participation sports screening

Echocardiography with conventional M-mode and 2D modalities is a simple and cost effective way to increases the accuracy of pre-participation sports screening, according to research presented at EuroEcho-Imaging 2013 by Dr Alexander Kisko from Presov, Slovakia.

14 Dec 2013

Cook Medical begins clinical study to evaluate removability of Evolution Esophageal Fully Covered Stent

Cook Medical has initiated a clinical study in the U.S. to evaluate the removability of a new Evolution Esophageal Fully Covered Stent. This is the first multicenter U.S. study to evaluate the possibility of removing a self-expanding metal stent after malignant and benign strictures have been treated. The stent design used in the study has been modified to accommodate retrieval.

12 Dec 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Enterocystoplasty: A good surgical option for children with genitourinary abnormalities

Enterocystoplasty is a good surgical option with a low rate of severe complications in the treatment of children who were born with developmental abnormalities of the genitourinary system, according to the new study conducted by a group of Portuguese urologists.

30 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments.

3 Oct 2013